Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial

Streptococcus pneumoniae infection is a major global public health concern in older adults, especially as life expectancy continues to increase in most countries, including India. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) with the ability to enhance immunity (immunologic memory) o...

Full description

Bibliographic Details
Main Authors: Bhagirath B. Solanki, Christine Juergens, Manojkumar B. Chopada, Pravin Supe, Vani Sundaraiyer, Natacha Le Dren-Narayanin, Mark W. Cutler, William C. Gruber, Daniel A. Scott, Beate Schmoele-Thoma
Format: Article
Language:English
Published: Taylor & Francis Group 2017-09-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
adults
india
immunogenicity
safety
thirteen-valent pneumococcal conjugate vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2017.1331796

Internet

http://dx.doi.org/10.1080/21645515.2017.1331796

Similar Items